FDA sinks Actinium's radiotherapy blood cancer filing plans, prompting pivot to partnering

[cafead]

via The FDA has torpedoed Actinium Pharmaceuticals’ hopes of winning a blood cancer approval based on existing data. With the agency requesting an additional head-to-head randomized clinical trial, Actinium is planning to try to partner the program and switch its attention to other candidates.

article source